Forma Therapeutics (FMTX) has filed a preliminary prospectus for a $150M IPO.
The Watertown, MA-based biopharmaceutical firm
develops small molecule treatments for rare blood diseases and cancer.
Lead candidate is FT-4202, an activator of an enzyme called pyruvate kinase-R
(PKR), for sickle cell disease. Deficient levels of PKR, located in red
blood cells, are associated with chronic hemolysis (rupture or
destruction of red blood cells).
2019 Financials: Collaboration
Revenue: $100.6M (-39%); Operating Expenses: $141.0M (-9%); Net Loss:
($53.7M) (-999%); Cash Flow Ops: ($34.5M) (+74%).
https://seekingalpha.com/news/3578778-forma-therapeutics-on-deck-for-ipo
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.